← Back to Search

Other

HDL Therapeutics PDS-2™ System for Hypercholesterolemia

N/A
Waitlist Available
Research Sponsored by HDL Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 months
Awards & highlights

Summary

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Eligible Conditions
  • Hypercholesterolemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in coronary atheroma

Side effects data

From 2005 Phase 3 trial • 80 Patients • NCT00180687
25%
Nausea and Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Control
IP Aerosolized Normal Saline
Nebulised Bupivacaine Intraperitoneally
Injected Bupivacaine Intraperitoneally

Trial Design

1Treatment groups
Experimental Treatment
Group I: HDL Therapeutics PDS-2™ SystemExperimental Treatment1 Intervention
Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Find a Location

Who is running the clinical trial?

HDL TherapeuticsLead Sponsor
MedStar Heart and Vascular InstituteUNKNOWN
~1 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top